Aura Biosciences, Inc. financial data

Symbol
AURA on Nasdaq
Location
Boston, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1069% % -39%
Debt-to-equity 20% % 40%
Return On Equity -70% % -68%
Return On Assets -58% % -60%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 63,503,269 shares 27%
Common Stock, Shares, Outstanding 62,985,569 shares 27%
Entity Public Float $191,700,000 USD -15%
Weighted Average Number of Shares Outstanding, Basic 65,936,672 shares 33%
Weighted Average Number of Shares Outstanding, Diluted 65,936,672 shares 33%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $90,738,000 USD 27%
General and Administrative Expense $22,625,000 USD 3.6%
Operating Income (Loss) $113,363,000 USD -22%
Nonoperating Income (Expense) $7,012,000 USD -31%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $106,351,000 USD -28%
Income Tax Expense (Benefit) $26,000 USD -40%
Net Income (Loss) Attributable to Parent $106,466,000 USD -28%
Earnings Per Share, Basic -1 USD/shares -11%
Earnings Per Share, Diluted -1 USD/shares -11%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $47,553,000 USD 87%
Other Assets, Current $2,585,000 USD -24%
Assets, Current $170,120,000 USD -7.3%
Property, Plant and Equipment, Net $2,629,000 USD -21%
Operating Lease, Right-of-Use Asset $16,230,000 USD -8.5%
Other Assets, Noncurrent $277,000 USD 1159%
Assets $190,024,000 USD -7.5%
Accounts Payable, Current $1,888,000 USD -5.2%
Liabilities, Current $18,823,000 USD 28%
Operating Lease, Liability, Noncurrent $14,534,000 USD -8.9%
Liabilities $33,357,000 USD 8.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax $69,000 USD -89%
Retained Earnings (Accumulated Deficit) $454,859,000 USD -31%
Stockholders' Equity Attributable to Parent $156,667,000 USD -10%
Liabilities and Equity $190,024,000 USD -7.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $23,355,000 USD 4.5%
Net Cash Provided by (Used in) Financing Activities $96,000 USD -62%
Net Cash Provided by (Used in) Investing Activities $29,813,000 USD 217%
Common Stock, Shares Authorized 150,000,000 shares 0%
Common Stock, Shares, Issued 62,985,569 shares 27%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $14,803,000 USD 82%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $48,321,000 USD 85%
Deferred Tax Assets, Valuation Allowance $105,851,000 USD 29%
Deferred Tax Assets, Gross $111,146,000 USD 27%
Operating Lease, Liability $17,754,000 USD -7%
Depreciation $1,208,000 USD 3%
Payments to Acquire Property, Plant, and Equipment $187,000 USD 112%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $107,004,000 USD -30%
Lessee, Operating Lease, Liability, to be Paid $25,187,000 USD -12%
Property, Plant and Equipment, Gross $9,472,000 USD 1.9%
Operating Lease, Liability, Current $3,220,000 USD 3%
Lessee, Operating Lease, Liability, to be Paid, Year Two $3,507,000 USD 3%
Lessee, Operating Lease, Liability, to be Paid, Year One $3,405,000 USD 3%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $7,433,000 USD -21%
Lessee, Operating Lease, Liability, to be Paid, Year Three $3,611,000 USD 3%
Deferred Tax Assets, Operating Loss Carryforwards $55,826,000 USD 21%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $3,715,000 USD 2.9%
Operating Lease, Payments $816,000 USD 8.7%
Additional Paid in Capital $611,457,000 USD 17%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $13,972,000 USD 23%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%